Skip to main content
Premium Trial:

Request an Annual Quote

Philip Huxley, Peter Buckel, Bernd Wetzel, Matthias Mann, Bruce Stillman, and Thomas Kelly


Galapagos Genomics said this week that it has appointed Philip Huxley as senior director of drug discovery.

Huxley was previously head of drug discovery at Avidex, according to Galapagos. Prior to this, he was head of molecular design at British Biotech. He holds a PhD in theoretical chemistry from the University of Sussex in Brighton.

"With the addition of Phil Huxley to the team, we can enter the targets into drug discovery and rapidly move compounds towards the clinic," Galapagos CEO Onno van de Stolpe said in a statement.

Atugen publicly announced the appointment of Peter Buckel as the company's CEO last week.

RNAi News reported Buckel's role at Atugen in late April (see RNAi News, 4/23/2004).

Buckel previously served as CEO of Xantos Biomedicine, a company he co-founded. Prior to this, he was senior vice president of molecular medicine for Roche Diagnostics. Buckel also currently serves as a professor at Ludwig-Maximillians-University, Institute of Microbiology and Genetics in Munich, and is on the advisory board of the Max-Planck Institute for Biochemistry and Neurobiology.

"We are delighted to welcome Prof Buckel," Jeremy Curnock Cook, chairman of Atugen's supervisory board, said in a statement. "His management experience in R&D will prove invaluable as Atugen moves to the next stage of its siRNA therapeutics development program whilst still managing its contract research business in target validation as a valuable source of revenue."

Atugen also said that Bernd Wetzel has been appointed non-executive director of the company.

Wetzel was formerly head of research and development at, and is a current member of the management board of, Boehringer Ingelheim.

Matthias Mann is to become a director at the Max Planck Institute for Biochemistry, effective May 1, 2005. He is currently the director of the Center for Experimental Bioinformatics at the University of Southern Denmark in Odense.

Bruce Stillman and Thomas Kelly have jointly received the annual Alfred P. Sloan, Jr. Prize, General Motors said this week. They share the $250,000 award, one of three prizes given annually by the General Motors Cancer Research Foundation, for their contributions to the understanding of DNA replications in eukaryotes. Stillman is the president and CEO of Cold Spring Harbor Laboratory in New York. Kelly is the director of the Sloan-Kettering Institute.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.